This week sees the start of the American Society of Clinical Oncology Symposium on Genitourinary Cancers (ASCO GU) in San Francisco.

Prostate cancer has certainly been in the minds of investors the past few weeks in anticipation of the COMET-1 prostate cancer trial results for cabozantinib (Cometriq).

The share price went on a run-up until Exelixis CEO Michael Morrissey took yet another trip to the biotech ATM machine.  Somehow, this doesn’t come as any surprise given past performance.  The key issue at stake here, however, is will the COMET-1 trial be positive or negative?  The outcome is much anticipated and will no doubt influence the chances of successful approval for cabozantinib in advanced prostate cancer.  Data is expected sometime in first half of this year.

What we can expect in the media this week is more news on the Medivation and Astellas phase 3 trial PREVAIL clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer who had not yet received chemotherapy.  The ASCO GU abstracts are publicly available at 5pm on Tuesday.

Currently, the key data from oncology medical conferences is focused squarely on Medivation’s enzalutamide and the PREVAIL data.  It seems a good idea to discuss what are the key things to watch out for?

You can sign in or sign-up below to read the report.

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTs & WRITERs), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.